


Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia

Michaela Liedtke,¹ Clare J. Twist,² Bruno C. Medeiros,¹ Jason R. Gotlib,¹ Caroline Berube,¹ Marcia M. Bieber,³ Neelima M. Bhat,³ Nelson N. Teng,³ and Steven E. Coutre¹

¹Departments of Medicine, ²Pediatrics and ³Gynecology, Stanford University School of Medicine, Stanford, CA, USA

Citation: Liedtke M, Twist CJ, Medeiros BC, Gotlib JR, Berube C, Bieber MM, Bhat NM, Teng NN, and Coutre SE. Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. Haematologica 2012;97(1):30-37. doi:10.3324/haematol.2011.045997



Online Supplementary Figure S1. Scanning electron microscopy image of B-cell ALL blasts treated with mAb216. Cells were incubated with 10 µg/mL of mAb216 for 15 min at 4 °C, washed three times with PBS and fixed with 2% glutaraldehyde and post fixed in 1% OsO₄, dehydrated in 30-100% ethanol and dried in hexamethyldisilazane. The cells were mounted onto a double sticky Pelco carbon conductive stub and gold coated on a Polaron 5300. The cells were examined by Philips 505 scanning electron microscope (Philips, Eindhoven, Holland) and images recorded on film. The print was scanned into jpeg.